PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis.
- Conditions
- First Posted Date
- 2023-01-19
- Last Posted Date
- 2024-04-05
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 183
- Registration Number
- NCT05689151
- Locations
- 🇫🇷
CHU Amiens-Picardie - Site Nord, Amiens, Somme, France
🇫🇷Chu Estaing, Clermont Ferrand Cedex 1, France
🇫🇷CHU Besancon - Hopital Jean Minjoz, Besancon, France
A Study to Understand the Long-term Safety and Effects of an Experimental Gene Therapy for Duchenne Muscular Dystrophy.
- Conditions
- Interventions
- First Posted Date
- 2023-01-19
- Last Posted Date
- 2024-02-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 250
- Registration Number
- NCT05689164
- Locations
- 🇺🇸
UCLA Children's Heart Center, Los Angeles, California, United States
🇺🇸UCLA Clinical Lab Services, Los Angeles, California, United States
🇺🇸Duke Lenox Baker Children's, Durham, North Carolina, United States
A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2023-01-17
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 44
- Registration Number
- NCT05687032
- Locations
- 🇨🇳
The First Hospital of Harbin, Harbin, Heilongjiang, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳Peking University Third Hospital, Beijing, Beijing, China
A Study to Learn How the Study Medicine (Ponsegromab) is Changed and Eliminated From Healthy Chinese Adults
- First Posted Date
- 2023-01-17
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 18
- Registration Number
- NCT05685264
- Locations
- 🇨🇳
HuaShan Hospital, Shanghai, Shanghai, China
🇨🇳Huashan Hospital Fudan University, Shanghai, Shanghai, China
A Study to Compare Two Different Forms of PF-07081532 in Adults Who Are Overweight or Obese
- Conditions
- Interventions
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2024-08-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 20
- Registration Number
- NCT05677867
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma
- Conditions
- Interventions
- First Posted Date
- 2023-01-09
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 90
- Registration Number
- NCT05675449
- Locations
- 🇺🇸
Sylvester Comprehensive Cancer Center - Aventura, Aventura, Florida, United States
🇺🇸Johns Hopkins Medicine, Baltimore, Maryland, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
A Study to Understand the Effect of a Study Medicine Called ARV-471 on Dabigatran Etexilate in Healthy Adults
- First Posted Date
- 2023-01-06
- Last Posted Date
- 2024-08-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 24
- Registration Number
- NCT05673889
- Locations
- 🇧🇪
Pfizer Clinical Research Unit - Brussels, Brussels, Bruxelles-capitale, Région DE, Belgium
A Study to Evaluate the Effect of the Experimental GLP-1 Drug PF-07081532 on Blood Levels of Common Birth Control Pills, and Drugs Omeprazole and Midazolam, and Effect of GLP-1 Drug Semaglutide on Midazolam Blood Levels in Healthy Adults With Weight in the Obesity Range
- First Posted Date
- 2023-01-05
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 32
- Registration Number
- NCT05671653
- Locations
- 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
A Study to Learn About Recifercept in Patients With Achondroplasia
- First Posted Date
- 2022-12-21
- Last Posted Date
- 2023-07-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 250
- Registration Number
- NCT05659719
- Locations
- 🇺🇸
Pfizer, New York, New York, United States
A Study to Learn About a New Medicine Called Vepdegestrant (ARV-471, PF-07850327) in People Who Have Advanced Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-12-16
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 624
- Registration Number
- NCT05654623
- Locations
- 🇺🇸
Morton Plant Hospital - BayCare Health System, Clearwater, Florida, United States
🇺🇸3T Radiology LLC, Coconut Creek, Florida, United States
🇺🇸Florida Cancer Specialists - South, Fort Myers, Florida, United States